Q3 2026 BWX Technologies Earnings Conference Call Webcast - BWX TECHNOLOGIES INC

Explicit Guidance:

• FY2026: Revised free cash flow guidance raised to $350–$360 million (previously lower end); adjusted EBITDA of ~$667 million; adjusted EPS of $4.72–$4.77; capital expenditures expected at ~6% of revenue.
• FY2027: Preliminary outlook expects high single-digit to low double-digit growth in adjusted EBITDA and adjusted EPS; Government Operations expects high single-digit to low double-digit revenue and EBITDA growth; Commercial Operations expects high single-digit organic revenue growth (low single-digit total due to medical divestiture) and high single-digit adjusted EBITDA growth with margins improving by 50–100 basis points; Free cash flow anticipated to be flat to slightly higher than 2026; capital expenditures continue at ~6% of revenue.
• Long-Term (2030): Reinforces Investor Day targets of $5.5–$6.0 billion revenue and $1.1–$1.2 billion adjusted EBITDA, supported by organic growth and capital allocation discipline; credit profile improvement supports ability to maintain 2–3x leverage.

Business-Segment Outlook:

• Government Operations: Special Materials (HPDU) to drive meaningful revenue growth through 2027 via the new Jonesboro, TN facility (initiated construction, $1.6B contract for 300 metric tons); HEU enrichment facility in Irwin, TN currently in design; Oak Ridge facility industrializing centrifuge technology with prototype testing planned by end of 2026. Technical Services expected to see a down-selection for the Y-12 lithium processing program in the first half of 2027.
• Advanced Nuclear: Project Pele reactor delivery to Idaho National Laboratory expected next year (2027); Janus program (20+ microreactors across 5 bases) in first phase including site selection at Fort Campbell; Banner reactor selected for Prodigy Clean Energy's project in New Brunswick, Canada (first international microreactor win); Antares awarded initial 1 metric ton of TRISO fuel manufactured on the Lynchburg line.
• Commercial Operations: Cambridge facility expansion completed, increasing heavy component manufacturing capacity by ~50%; final investment decision (FID) for a new U.S. commercial manufacturing facility for steam generators and reactor pressure vessels expected by end of 2026; Medical divestiture on track to close later in 2026; PCG acquisition integration progressing well with no specific synergy targets released, but cost opportunities identified.

Market and Competitive Outlook:

• Demand Trends: Commercial nuclear demand described as "precipitating rapidly," expected to shift from a "trickle to a flood" with firm orders anticipated in 2027 and beyond; Global interest in nuclear power is high, specifically in Poland (potential microreactor and SMR deployment) and U.S. (SMR and large reactor programs).
• Competitive Positioning: BWXT views itself as a "supermerchant supplier" capable of delivering integrated solutions (reactor, fuel, lifecycle services); expects to compete globally for AP1000 and other reactor components; identifies the 20-MWe Banner reactor as a differentiated asset suitable for large military bases and industrial heat, unlike smaller microreactors.
• Order Flow: Anticipates new orders for U.S. reactor plant builds (SMRs and large reactors) by end of 2026 or first half of 2027; sequencing expected as: Darlington project (Canada) → TVA projects (Clinch River/Bellefonte) → AP1000 projects (South Korea/Japan funded).

Macro / Industry Outlook:

• Economic & Political Support: Strong bipartisan support for nuclear energy; deals structured outside congressional appropriations are expected to proceed regardless of mid-term election outcomes or budget continuing resolutions.
• Financing & Risk: Gating items for new builds are identified as allocation of risk (distribution of overruns among utility, government, and technology provider) rather than pure financing; sovereign investments from South Korea and Japan expected to fund specific reactor tranches.
• Regulation: Nuclear regulatory processes for the Janus program are being initiated; TRISO fuel production scaling is a key focus.

Strategic Initiatives:

• Capacity Expansion: Completed 50% capacity increase at Cambridge, Ontario; planning new U.S. facility for large components (FID end of 2026); expanding TRISO fuel capacity at Lynchburg to quadruple output in the near term; potential future multi-metric ton capacity expansion (e.g., Wyoming) contingent on demand precipitation (Kairos Hermes anchor, multiple Banner orders) and HALU availability.
• M&A: No specific M&A targets announced; PCG acquisition closed in July 2026; focus remains on organic growth, with balance sheet flexibility to pursue disciplined acquisitions.
• Divestiture: Medical business divestiture expected to close later in 2026, impacting 2027 total revenue growth guidance but not organic growth guidance.
• AI Adoption: Rapid adoption of AI by Technical Services teams to drive site performance and efficiency.

Risks and Headwinds to Outlook:

• Margin Mix: Scaling new programs (Special Materials, Advanced Nuclear) may create margin mix effects, though operational improvements are expected to offset this; Medical divestiture is a margin mix headwind (loss of higher margin business).
• Working Capital & Cash: Potential headwinds from ~$10 million pension contribution increase and working capital investments for growth; HPDU and enrichment program milestone timing impacts cash flow.
• Risk Allocation: Project delivery risk and risk allocation (not component manufacturing risk) remain the primary gating factors for FID on new commercial builds.
• Technology Gates: Future TRISO capacity expansion depends on commercial availability of HALU and concrete demand precipitation from partners like Kairos.

Management Tone on the Future:

• Confidence: High confidence in achieving 2030 financial targets; "exceptionally strong" year-to-date performance reinforces the long-term outlook.
• Execution Focus: Emphasis on converting the bid pipeline into firm awards and scaling industrial capabilities; management views the current backlog and program momentum as a "solid foundation" for continued earnings growth.
• Capital Allocation: Clear priority on organic growth investments, with shareholder returns (share repurchases) contingent on excess capital after growth opportunities are met; balance sheet strength viewed as a competitive advantage.

Miscellaneous:

• Pension: $10 million headwind to 2027 free cash flow attributed to the Kinetrix acquisition.
• Backlog: PCG acquisition added ~$500 million to backlog; 50% of PCG business remains in naval work (low single-digit growth expected), with commercial growth driven by tapping unutilized capacity.
• Credit Profile: Fitch granted inaugural investment grade rating; Moody's revised outlook to positive.